<DOC>
	<DOCNO>NCT00434122</DOCNO>
	<brief_summary>The main purpose clinical research study investigate degarelix synchronise growth egg sac ovary degarelix effect lining womb .</brief_summary>
	<brief_title>Exploratory Study Assessing Synchronisation Egg Sacs With Degarelix</brief_title>
	<detailed_description>For primary end-point ( data collect Stimulation Day 1 ) , study compare degarelix 2.5 mg administer mid-luteal phase placebo administer mid-luteal phase . After Stimulation Day 1 placebo group split two group : degarelix 2.5 mg follicular group ganirelix 0.25 mg group .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Infertility , Female</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Inclusion Criteria Signed Informed Consent Form , prior screen evaluation In good physical mental health Premenopausal females age 1835 year ( inclusive ) time randomisation Regular menstrual cycle 2635 day duration ( inclusive ) , presumed ovulatory Body mass index ( BMI ) 18 29 kg/m2 ( inclusive ) Willing donate retrieve oocyte Willing use adequate barrier method contraception inform consent Day hCG injection +7 use adequate barrier hormonal method contraception Day hCG injection +7 endofstudy visit Exclusion Criteria Abnormal karyotype Any know clinically significant systemic disease ( e.g. , insulin dependent diabetes ) Any know endocrine metabolic abnormality ( pituitary , adrenal , pancreas , liver kidney ) compromise participation study Diagnosed polycystic ovarian syndrome endometriosis stage III/IV Diagnosed `` poor responder '' History recurrent miscarriage ( define three consecutive spontaneous loss week 24 pregnancy ) Pregnancy lactation Use investigational drug 3 month prior start current COH cycle Previous participation study Hypersensitivity trial product</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Assisted Reproductive Technology ( ART )</keyword>
	<keyword>oocyte donor undergo control ovarian hyperstimulation assist reproductive technology</keyword>
</DOC>